SCHEMBL755869

SCHEMBL755869

CCCCS(=O)(=O)CC[C@H](N)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCLC P48506 1/20 0.59
PMP22 Q01453 2/20 0.53
SLC1A2 P43004 4/20 0.50
SLC1A1 P43005 4/20 0.50
SLC1A3 P43003 3/20 0.50
GRIK1 P39086 5/20 0.49
GRIK2 Q13002 4/20 0.49
DDAH1 O94760 3/20 0.46
GSR P00390 2/20 0.44
NOS1 P29475 3/20 0.44
NOD1 Q9Y239 2/20 0.42
GRM8 O00222 1/20 0.42
GRM6 O15303 1/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
CYP1A2 P05177 1/20 0.42
GRM5 P41594 1/20 0.42
GRIA1 P42261 1/20 0.42
GRIA2 P42262 1/20 0.42
GRIA3 P42263 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11738674 1.00 GCLC (0.59) GCLCPMP22SLC1A2SLC1A1SLC1A3
SCHEMBL11739545 0.88 GCLC (0.62) GCLCPMP22SLC1A2SLC1A1SLC1A3
SCHEMBL31661813 0.85 GCLC (0.62) GCLCPMP22SLC1A2SLC1A1SLC1A3
SCHEMBL11735940 0.84 GCLC (0.67) GCLCPMP22SLC1A2SLC1A1SLC1A3
SCHEMBL1157698 0.84 GCLC (0.67) GCLCPMP22SLC1A2SLC1A1SLC1A3
Buthionine Sulfoxime SCHEMBL121171 0.81 PMP22 (0.59) GCLCPMP22SLC1A2SLC1A1SLC1A3
Buthionine Sulfoxime SCHEMBL115963 0.81 PMP22 (0.59) GCLCPMP22SLC1A2SLC1A1SLC1A3
Buthionine Sulfoxime SCHEMBL62034 0.81 PMP22 (0.59) GCLCPMP22SLC1A2SLC1A1SLC1A3
Buthionine Sulfoxime SCHEMBL9300391 0.81 PMP22 (0.59) GCLCPMP22SLC1A2SLC1A1SLC1A3
Buthionine Sulfoxime SCHEMBL4449935 0.81 PMP22 (0.59) GCLCPMP22SLC1A2SLC1A1SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4376995-A1 BIOBASED CORE-SHELL MICROCAPSULES Symrise AG (DE) 2024-06-05 EP disclosed
EP-3432858-B1 NON-THERAPEUTIC USE OF CARNOSINES SYMRISE AG (DE) 2023-12-27 EP disclosed
EP-4252737-A1 SUNSCREEN COMPOSITION FOR PROTECTING THE SKIN FROM VISIBLE LIGHT STADA ARZNEIMITTEL AG (DE) 2023-10-04 EP disclosed
US-11773060-B2 Method for synthesis of 9-cis-beta-carotene and formulations thereof RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2023-10-03 US disclosed
EP-3536383-B1 CLEANING AND CARE PREPARATIONS COMPRISING A POLYOXYALKYLENE CARBOXYLATE PERFECT IDEAS GMBH (CH) 2023-09-27 EP disclosed
EP-3536769-B1 WASHING AND CLEANING COMPOSITION COMPRISING A POLYOXYALKYLENE CARBOXYLATE PERFECT IDEAS GMBH (CH) 2023-08-16 EP disclosed
EP-2034949-B2 METHOD FOR INCREASING THE SUN PROTECTION FACTOR OF A COSMETIC AND/OR DERMATOLOGICAL PREPARATION BASF SE (DE) 2023-06-28 EP disclosed
CN-116348086-A Surfactant-containing formulations of ceramide 西姆莱斯股份公司 2023-06-27 CN disclosed
CN-115942870-A Composition with virucidal and/or antiviral activity 西姆莱斯股份公司 2023-04-07 CN disclosed
CN-115701970-A Method for producing a personalized cosmetic preparation 巴斯夫欧洲公司 2023-02-14 CN disclosed
US-5961959-A Cosmetic and dermatological light protection formulations having a content of triazine derivatives and monoesters and diesters of branched alkanecarboxylic acids and diglycerol or triglycerol BEIERSDORF AG (DE) 1999-10-05 US disclosed
US-5952373-A APPLYING TO THE SKIN AN EFFECTIVE AMOUNT OF ONE OR MORE FLAVONOIDS BEIERSDORF AG (DE) 1999-09-14 US disclosed
US-5876737-A SKIN DISORDERS BEIERSDORF AG (DE) 1999-03-02 US disclosed
US-5876702-A Cosmetic and dermatological light protection formulations in the form of O/W macroemulsions, O/W microemulsions or O/W/O emulsions BEIERSDORF AG (DE) 1999-03-02 US disclosed
US-5851542-A Cosmetic and dermatological light protection formulations having a content of triazine derivatives and glycerol mono- or dicarboxylic acid monoesters BEIERSDORF AG (DE) 1998-12-22 US disclosed
US-5833951-A OILS, FATS AND/OR WAXES, THICKENERS AND ADDITIVES BEIERSDORF AG (DE) 1998-11-10 US disclosed
US-5804167-A OILY PHASE OF NON-POLAR FATS OR WAXES; ONE OR MORE SALTS OF DI- OR TRIVALENT METAL CATIONS AND ONE OR MORE ALKYLCARBOXYLIC ACIDS HAVING 10 TO 24 CARBON ATOMS BEIERSDORF AG (DE) 1998-09-08 US disclosed
US-5783176-A CONTAINING ESTER FROM HYDROXYCARBOXYLIC ACID AND SATURATEDALCOHOL; CARING OF LIPS BEIERSDORF AG (DE) 1998-07-21 US disclosed
US-5759584-A Method for treating skin afflicted with blemishes or acne with a composition comprising distilled wool wax acids and at least one monoglycerol monocarboxylic acid monoester BEIERSDORF AG (DE) 1998-06-02 US disclosed
US-5750124-A W/O/W emulsions BEIERSDORF AG (DE) 1998-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773060-B2 Method for synthesis of 9-cis-beta-carotene and formulations thereof BHMT2, CBS, TTPA GCLC 53/4885PMP22 4257/4885SLC1A2 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.